OBJECTIVE: To review the literature on the epidemiology of Campylobacter-associated reactive arthritis (ReA). METHODS: A Medline (PubMed) search identified studies from 1966 to 2006 that investigated the epidemiology of Campylobacter-associated ReA. Search terms included: "reactive arthritis," "spondyloarthropathy," "Reiter's syndrome," "gastroenteritis," "diarrhea," "epidemiology," "incidence," "prevalence," and "Campylobacter." RESULTS: The literature available to date suggests that the incidence of Campylobacter ReA may occur in 1 to 5% of those infected. The annual incidence of ReA after Campylobacter or Shigella may be 4.3 and 1.3, respectively, per 100,000. The duration of acute ReA varies considerably among reports, and the incidence and impact of chronic ReA from Campylobacter infection is virtually unknown. CONCLUSIONS: Campylobacter-associated ReA incidence and prevalence varies widely among reviews due to case ascertainment differences, exposure differences, lack of diagnostic criteria for ReA, and perhaps genetics and ages of exposed individuals. At the population level it may not be associated with HLA-B27, and inflammatory back involvement is uncommon. Follow-up for long-term sequelae is largely unknown. Five percent of Campylobacter ReA may be chronic or relapsing (with respect to musculoskeletal symptoms).
OBJECTIVE: To review the literature on the epidemiology of Campylobacter-associated reactive arthritis (ReA). METHODS: A Medline (PubMed) search identified studies from 1966 to 2006 that investigated the epidemiology of Campylobacter-associated ReA. Search terms included: "reactive arthritis," "spondyloarthropathy," "Reiter's syndrome," "gastroenteritis," "diarrhea," "epidemiology," "incidence," "prevalence," and "Campylobacter." RESULTS: The literature available to date suggests that the incidence of Campylobacter ReA may occur in 1 to 5% of those infected. The annual incidence of ReA after Campylobacter or Shigella may be 4.3 and 1.3, respectively, per 100,000. The duration of acute ReA varies considerably among reports, and the incidence and impact of chronic ReA from Campylobacter infection is virtually unknown. CONCLUSIONS: Campylobacter-associated ReA incidence and prevalence varies widely among reviews due to case ascertainment differences, exposure differences, lack of diagnostic criteria for ReA, and perhaps genetics and ages of exposed individuals. At the population level it may not be associated with HLA-B27, and inflammatory back involvement is uncommon. Follow-up for long-term sequelae is largely unknown. Five percent of Campylobacter ReA may be chronic or relapsing (with respect to musculoskeletal symptoms).
Authors: T U Kosunen; A Pönkä; O Kauranen; J Martio; T Pitkänen; L Hortling; S Aittoniemi; O Penttilä; S Koskimies Journal: Scand J Rheumatol Date: 1981 Impact factor: 3.641
Authors: L B van de Putte; J H Berden; M T Boerbooms; W H Muller; J J Rasker; A Reynvaan-Groendijk; S M van der Linden Journal: J Rheumatol Date: 1980 Jul-Aug Impact factor: 4.666
Authors: Z Islam; S K Sarker; I Jahan; K S Farzana; D Ahmed; A S G Faruque; P Guerry; F Poly; A P Heikema; H P Endtz Journal: Eur J Clin Microbiol Infect Dis Date: 2017-12-21 Impact factor: 3.267
Authors: Hayley J Denison; Elizabeth M Curtis; Michael A Clynes; Collette Bromhead; Elaine M Dennison; Rebecca Grainger Journal: Clin Rheumatol Date: 2016-08-01 Impact factor: 2.980
Authors: Shawn Vasoo; Jeramy J Schwab; Scott A Cunningham; Trisha J Robinson; Joseph R Cass; Elie F Berbari; Randall C Walker; Douglas R Osmon; Robin Patel Journal: J Clin Microbiol Date: 2014-02-12 Impact factor: 5.948
Authors: Jennifer A Curry; Mark S Riddle; Robert P Gormley; David R Tribble; Chad K Porter Journal: BMC Infect Dis Date: 2010-09-13 Impact factor: 3.090
Authors: Shahida Baqar; Lisa A Applebee; Theron C Gilliland; Lanfong H Lee; Chad K Porter; Patricia Guerry Journal: Infect Immun Date: 2008-04-21 Impact factor: 3.441